Doctors Identify Rare Invasive Nipple Melanoma
A 93-year-old patient remains disease-free after treatment for a rare melanoma initially misdiagnosed as sarcoma.
Updated on Oct. 26, 2026 in Cancer
Medical professionals successfully treated a 93-year-old woman for invasive nipple melanoma in 2024 after an initial biopsy suggested a sarcoma diagnosis. The patient remains disease-free 26 months following a modified radical mastectomy.
Why it matters
The case highlights the critical importance of accurate immunohistochemical testing in diagnosing rare breast lesions that may mimic other malignancies. Correct identification allowed the medical team to forgo unnecessary adjuvant therapy given the patient's advanced age.
Histopathological analysis confirmed a Breslow thickness of at least 60 mm and a mitotic rate of 7 mitoses/mm² in the ulcerated lesion. All 15 dissected axillary lymph nodes tested negative for malignancy.
The details
Clinicians performed immunohistochemical testing for S100, Melan-A, HMB45, PRAME, and tyrosinase to confirm the diagnosis after initial tools suggested undifferentiated sarcoma. The patient underwent a modified radical mastectomy and axillary lymph node dissection to remove the 44 by 35 mm mass.
Timeline
The patient remained disease-free 26 months after the initial surgery.
Health Landscape
The case follows the standardized staging protocols established by the American Joint Committee on Cancer (AJCC) staging manual to classify the severity of the malignancy. This retrospective analysis illustrates how refined diagnostic techniques prevent misclassification of complex skin lesions.
This report emphasizes that elderly patients presenting with ulcerated lesions require thorough immunohistochemical testing to differentiate rare melanomas from other tissue cancers. The successful outcome demonstrates that age alone should not preclude aggressive surgical intervention when justified by clinical findings.
The takeaway
This case demonstrates the efficacy of surgical intervention in treating aggressive skin cancers even among the oldest patient populations. Accurate diagnostic testing remains the most vital step in determining whether patients can avoid the complications of adjuvant therapy.
Further reading
Learn more about the latest developments in oncology through our Cancer section.
